1
|
Racaniello GF, Laquintana V, Vergnaud J, Lopedota A, Cutrignelli A, Lopalco A, Leonetti F, Franco M, Fiume M, Pontrelli P, Gesualdo L, Fattal E, Denora N. Development of purified glycogen derivatives as siRNA nanovectors. Int J Pharm 2021; 608:121128. [PMID: 34560204 DOI: 10.1016/j.ijpharm.2021.121128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 09/17/2021] [Accepted: 09/18/2021] [Indexed: 10/20/2022]
Abstract
Purified Glycogen (PG) is a highly hyper branched carbohydrate, characterized by high water solubility and very moderate increase in viscosity. The dendrimeric structure of PG, appropriately functionalized, makes it an alternative to current synthetic gene delivery agents. The present study explores the preparation of purified glycogen polycationic derivatives (PGPDs), developed and characterized starting from a single step reaction between PG and N,N-dialkylamino alkyl halides. Subsequently PGPDs were used for the complexation of a model siRNA nucleic acid, a transfection reagent siRNA and a fluorescein-labelled dsRNA oligomer. PGPDs-siRNA complexes were fully characterized by agarose gel electrophoresis and their efficacy was assessed by both confocal microscopy and transfection assays on breast and renal cancer cells. Results proved that PGPDs-siRNA complexes were efficient and not cytotoxic, maintaining their spherical and dendrimeric structure and, particularly, were able to effectively transfect the target cells by releasing the siRNA.
Collapse
Affiliation(s)
| | - Valentino Laquintana
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Juliette Vergnaud
- Institut Galien Paris-Saclay, UMR CNRS 8612, Université Paris Saclay, Châtenay-Malabry, Paris, France
| | - Angela Lopedota
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Annalisa Cutrignelli
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Antonio Lopalco
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Francesco Leonetti
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Massimo Franco
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Mauro Fiume
- Department of Emergency and Organ Transplantation, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Paola Pontrelli
- Department of Emergency and Organ Transplantation, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Loreto Gesualdo
- Department of Emergency and Organ Transplantation, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy
| | - Elias Fattal
- Institut Galien Paris-Saclay, UMR CNRS 8612, Université Paris Saclay, Châtenay-Malabry, Paris, France
| | - Nunzio Denora
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy.
| |
Collapse
|
2
|
Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy. J Immunother 2020; 42:119-125. [PMID: 30933045 DOI: 10.1097/cji.0000000000000263] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Despite encouraging clinical results with immune checkpoint inhibitors and other types of immunotherapies, the rate of failure is still very high. The development of proper animal models which could be applied to the screening of effective preclinical antitumor drugs targeting human tumor antigens, such as mesothelin (MSLN), is a great need. MSLN is a 40 kDa cell-surface glycoprotein which is highly expressed in a variety of human cancers, and has great value as a target for antibody-based therapies. The present study reports the establishment of an immunocompetent transgenic mouse expressing human MSLN (hMSLN) only in thyroid gland by utilizing an expression vector containing a thyroid peroxidase (TPO) promoter. These mice do not reject genetically modified tumor cells expressing hMSLN on the cell membrane, and tolerate high doses of hMSLN-targeted immunotoxin. Employing this TPO-MSLN mouse model, we find that the combination treatment of LMB-100 and anti-CTLA-4 induces complete tumor regression in 91% of the mice burdened with 66C14-M tumor cells. The combination therapy provides a significant survival benefit compared with both LMB-100 and anti-CTLA-4 monotherapy. In addition, the cured mice reject tumor cells when rechallenged, indicating the development of long-term antitumor immunity. This novel TPO-MSLN mouse model can serve as an important animal tool to better predict tumor responses to any immunomodulatory therapies that target MSLN.
Collapse
|
3
|
White M, Freistaedter A, Jones GJB, Zervos E, Roper RL. Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer. PLoS One 2018; 13:e0193131. [PMID: 29474384 PMCID: PMC5825036 DOI: 10.1371/journal.pone.0193131] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Accepted: 02/05/2018] [Indexed: 11/25/2022] Open
Abstract
Pancreatic cancer is the 5th leading cause of cancer deaths, and there are no effective treatments. We developed a poxvirus platform vaccine with improved immunogenicity and inserted the mesothelin gene to create an anti-mesothelin cancer vaccine. Mesothelin expression is mostly restricted to tumors in adult mammals and thus may be a good target for cancer treatment. We show here that the modified vaccinia virus Ankara (MVA) virus expressing mesothelin and the enhanced MVA virus missing the immunosuppressive A35 gene and expressing mesothelin were both safe in mice and were able to induce IFN-gamma secreting T cells in response to mesothelin expressing tumor cells. In addition, the MVA virus has oncolytic properties in vitro as it can replicate in and kill Panc02 pancreatic adenocarcinoma cell line tumor cells, even though it is unable to replicate in most mammalian cells. Deletion of the A35 gene in MVA improved T cell responses as expected. However, we were unable to demonstrate inhibition of Panc02 tumor growth in immunocompetent mice with pre-vaccination of mice, boosts, or even intratumoral injections of the recombinant viruses. Vaccine efficacy may be limited by shedding of mesothelin from tumor cells thus creating a protective screen from the immune system.
Collapse
Affiliation(s)
- Michael White
- Department of Surgery, Brody School of Medicine, East Carolina University, Greenville, NC, United States of America
| | - Andrew Freistaedter
- Department of Microbiology, Brody School of Medicine, East Carolina University, Greenville, NC, United States of America
| | - Gwendolyn J B Jones
- Department of Microbiology, Brody School of Medicine, East Carolina University, Greenville, NC, United States of America
| | - Emmanuel Zervos
- Department of Surgery, Brody School of Medicine, East Carolina University, Greenville, NC, United States of America
| | - Rachel L Roper
- Department of Microbiology, Brody School of Medicine, East Carolina University, Greenville, NC, United States of America
| |
Collapse
|
4
|
Zervos E, Agle S, Freistaedter AG, Jones GJB, Roper RL. Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2016; 35:39. [PMID: 26931187 PMCID: PMC4774190 DOI: 10.1186/s13046-016-0314-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Accepted: 02/24/2016] [Indexed: 12/15/2022]
Abstract
Background Mesothelin has attracted much interest as a tumor specific antigen; it has been reported to promote tumor development and to be a good target for cancer treatment. Most studies to date have used human mesothelin in immunocompromised mice. Since these models do not allow for study of the natural immune response to mesothelin expressing tumors, we have undertaken the characterization of mouse mesothelin so the effects of this protein can be assessed in immunocompetent mouse strains. Methods We analyzed mouse mesothelin expression, tissue distribution, shedding and biochemistry. In addition we constructed stable mesothelin overexpressing lines of the pancreatic cancer line Panc02 by two methods and tested them for growth and tumorigencity in vitro and in vivo. Results We show here that mouse mesothelin is similar to human mesothelin in biochemical characteristics, tumor expression and tissue distribution, suggesting the mouse may be a suitable model for study of mesothelin. Stable overexpression of mesothelin in a pancreatic cancer cell line did not increase cell proliferation or anchorage-independent growth in vitro, suggesting that mesothelin is not necessarily a tumor progression factor. Surprisingly overexpression of mesothelin inhibited tumor formation in vivo in immunocompetent mice. Conclusion The mouse may be a good model for studying mesothelin in the context of an intact immune response. Mesothelin is not necessarily a tumor progression factor, and indeed mesothelin overexpression inhibited tumor growth in immunocompetent mice.
Collapse
Affiliation(s)
- Emmanuel Zervos
- Department of Surgery, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Rm 5E106A mailstop 629, Greenville, NC, 27834, USA.
| | - Steven Agle
- Department of Surgery, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Rm 5E106A mailstop 629, Greenville, NC, 27834, USA.
| | - Andrew G Freistaedter
- Microbiology & Immunology, East Carolina University Brody School of Medicine, Greenville, USA.
| | - Gwendolyn J B Jones
- Microbiology & Immunology, East Carolina University Brody School of Medicine, Greenville, USA.
| | - Rachel L Roper
- Microbiology & Immunology, East Carolina University Brody School of Medicine, Greenville, USA.
| |
Collapse
|
5
|
Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS One 2014; 9:e85935. [PMID: 24465798 PMCID: PMC3897543 DOI: 10.1371/journal.pone.0085935] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2013] [Accepted: 12/03/2013] [Indexed: 11/18/2022] Open
Abstract
Genes involved in the carcinogenetic mechanisms underlying malignant pleural mesothelioma (MPM) are still poorly characterized. So far, mesothelin (MSLN) has aroused the most interest. It encodes for a membrane glycoprotein, frequently over-expressed in various malignancies such as MPM, and ovarian and pancreatic cancers. It has been proposed as a diagnostic and immunotherapeutic target with promising results. However, an alternative therapeutic approach seems to rise, whereby synthetic molecules, such as antisense oligonucleotides, could be used to inhibit MSLN activity. To date, such a gene-level inhibition has been attempted in two studies only, both on pancreatic and ovarian carcinoma cell lines, with the use of silencing RNA approaches. With regard to MPM, only one cell line (H2373) has been employed to study the effects of MSLN depletion. Indeed, the knowledge on the role of MSLN in MPM needs expanding. Accordingly, we investigated the expression of MSLN in a panel of three MPM cell lines, i.e., NCI-H28, Mero-14, and IstMes2; one non-MPM cell line was used as reference (Met5A). MSLN knock-down experiments on MSLN-overexpressing cells were also performed through silencing RNA (siRNA) to verify whether previous findings could be generalized to a different set of cell cultures. In agreement with previous studies, transient MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. Moreover, MSLN-siRNA combined with cisplatin, triggered a marked increase in apoptosis and a decrease in proliferation as compared to cells treated with each agent alone, thereby suggesting a sensitizing effect of siRNA towards cisplatin. In summary, our findings confirm that MSLN should be considered a key molecular target for novel gene-based targeted therapies of cancer.
Collapse
Affiliation(s)
| | - Justin Stebbing
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Ylenia Lombardo
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Elisa Bracci
- Department of Biology, University of Pisa, Pisa, Italy
| | - Norihisa Uehara
- Second Department of Pathology, Kansai Medical University, Moriguchi-Shi, Osaka, Japan
| | - Alessandra Bonotti
- Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, Pisa, Italy
| | - Alfonso Cristaudo
- Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, Pisa, Italy
| | - Rudy Foddis
- Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, Pisa, Italy
| | - Luciano Mutti
- Laboratory of Clinical Oncology, Vercelli National Health Trust, Vercelli, Italy
| | | | | | - Georgios Giamas
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Stefano Landi
- Department of Biology, University of Pisa, Pisa, Italy
| |
Collapse
|
6
|
Stegh AH. Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) 2013; 5:48-65. [PMID: 22858688 DOI: 10.1039/c2ib20104f] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Tumors are composed of highly proliferate, migratory, invasive, and therapy-evading cells. These characteristics are conferred by an enormously complex landscape of genomic, (epi-)genetic, and proteomic aberrations. Recent efforts to comprehensively catalogue these reversible and irreversible modifications have began to identify molecular mechanisms that contribute to cancer pathophysiology, serve as novel therapeutic targets, and may constitute biomarkers for early diagnosis and prediction of therapy responses. With constantly evolving technologies that will ultimately enable a complete survey of cancer genomes, the challenges for discovery cancer science and drug development are daunting. Bioinformatic and functional studies must differentiate cancer-driving and -contributing mutations from mere bystanders or 'noise', and have to delineate their molecular mechanisms of action as a function of collaborating oncogenic and tumor suppressive signatures. In addition, the translation of these genomic discoveries into meaningful clinical endpoints requires the development of co-extinction strategies to therapeutically target multiple cancer genes, to robustly deliver therapeutics to tumor sites, and to enable widespread dissemination of therapies within tumor tissue. In this perspective, I will describe the most current paradigms to study and validate cancer gene function. I will highlight advances in the area of nanotechnology, in particular, the development of RNA interference (RNAi)-based platforms to more effectively deliver therapeutic agents to tumor sites, and to modulate critical cancer genes that are difficult to target using conventional small-molecule- or antibody-based approaches. I will conclude with an outlook on the deluge of challenges that genomic and bioengineering sciences must overcome to make the long-awaited era of personalized nano-medicine a clinical reality for cancer patients.
Collapse
Affiliation(s)
- Alexander H Stegh
- Ken and Ruth Davee Department of Neurology, The Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
| |
Collapse
|
7
|
Fathabadi EG, Shelling AN, Al-Kassas R. Nanocarrier systems for delivery of siRNA to ovarian cancer tissues. Expert Opin Drug Deliv 2012; 9:743-54. [DOI: 10.1517/17425247.2012.683173] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Kiryu H, Terai G, Imamura O, Yoneyama H, Suzuki K, Asai K. A detailed investigation of accessibilities around target sites of siRNAs and miRNAs. ACTA ACUST UNITED AC 2011; 27:1788-97. [PMID: 21531769 DOI: 10.1093/bioinformatics/btr276] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
MOTIVATION The importance of RNA sequence analysis has been increasing since the discovery of various types of non-coding RNAs transcribed in animal cells. Conventional RNA sequence analyses have mainly focused on structured regions, which are stabilized by the stacking energies acting on adjacent base pairs. On the other hand, recent findings regarding the mechanisms of small interfering RNAs (siRNAs) and transcription regulation by microRNAs (miRNAs) indicate the importance of analyzing accessible regions where no base pairs exist. So far, relatively few studies have investigated the nature of such regions. RESULTS We have conducted a detailed investigation of accessibilities around the target sites of siRNAs and miRNAs. We have exhaustively calculated the correlations between the accessibilities around the target sites and the repression levels of the corresponding mRNAs. We have computed the accessibilities with an originally developed software package, called 'Raccess', which computes the accessibility of all the segments of a fixed length for a given RNA sequence when the maximal distance between base pairs is limited to a fixed size W. We show that the computed accessibilities are relatively insensitive to the choice of the maximal span W. We have found that the efficacy of siRNAs depends strongly on the accessibility of the very 3'-end of their binding sites, which might reflect a target site recognition mechanism in the RNA-induced silencing complex. We also show that the efficacy of miRNAs has a similar dependence on the accessibilities, but some miRNAs also show positive correlations between the efficacy and the accessibilities in broad regions downstream of their putative binding sites, which might imply that the downstream regions of the target sites are bound by other proteins that allow the miRNAs to implement their functions. We have also investigated the off-target effects of an siRNA as a potential RNAi therapeutic. We show that the off-target effects of the siRNA have similar correlations to the miRNA repression, indicating that they are caused by the same mechanism. AVAILABILITY The C++ source code of the Raccess software is available at http://www.ncrna.org/software/Raccess/ The microarray data on the measurements of the siRNA off-target effects are also available at the same site. CONTACT kiryu-h@k.u-tokyo.ac.jp
Collapse
Affiliation(s)
- Hisanori Kiryu
- Department of Computational Biology, Faculty of Frontier Science, The University of Tokyo, Chiba 277-8561, Japan.
| | | | | | | | | | | |
Collapse
|
9
|
Zhang D, Kobayashi T, Kojima T, Kanenishi K, Hagiwara Y, Abe M, Okura H, Hamano Y, Sun G, Maeda M, Jishage KI, Noda T, Hino O. Deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 knockout mice. Cancer Sci 2011; 102:720-7. [PMID: 21205090 DOI: 10.1111/j.1349-7006.2011.01846.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Genetic crossing experiments were performed between tuberous sclerosis-2 (Tsc2) KO and expressed in renal carcinoma (Erc) KO mice to analyze the function of the Erc/mesothelin gene in renal carcinogenesis. We found the number and size of renal tumors were significantly less in Tsc2+/-;Erc-/- mice than in Tsc2+/-;Erc+/+ and Tsc2+/-;Erc+/- mice. Tumors from Tsc2+/-;Erc-/- mice exhibited reduced cell proliferation and increased apoptosis, as determined by proliferating cell nuclear antigen (Ki67) and TUNEL analysis, respectively. Adhesion to collagen-coated plates in vitro was enhanced in Erc-restored cells and decreased in Erc-suppressed cells with siRNA. Tumor formation by Tsc2-deficient cells in nude mice was remarkably suppressed by stable knockdown of Erc with shRNA. Western blot analysis showed that the phosphorylation of focal adhesion kinase, Akt and signal transducer and activator of transcription protein 3 were weaker in Erc-deficient/suppressed cells compared with Erc-expressed cells. These results indicate that deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 KO mice and inhibits the phosphorylation of several kinases of cell adhesion mechanism. This suggests that Erc/mesothelin may have an important role in the promotion and/or maintenance of carcinogenesis by influencing cell-substrate adhesion via the integrin-related signal pathway.
Collapse
Affiliation(s)
- Danqing Zhang
- Department of Pathology and Oncology, Juntendo University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Gao W, Xiao Z, Radovic-Moreno A, Shi J, Langer R, Farokhzad OC. Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol Biol 2010; 629:53-67. [PMID: 20387142 DOI: 10.1007/978-1-60761-657-3_4] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Nanoparticles made from synthetic polymers have been developed to deliver small interfering RNA (siRNA). For successful siRNA delivery, these nanoparticles need to efficiently encapsulate siRNA, actively target sites of interest, and release siRNA intracellularly. This chapter reviews recent progress using a multifunctional approach to design and engineer polymeric nanoparticles for siRNA delivery.
Collapse
Affiliation(s)
- Weiwei Gao
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | |
Collapse
|
11
|
Brunner T, Cohen S, Monsonego A. Silencing of proinflammatory genes targeted to peritoneal-residing macrophages using siRNA encapsulated in biodegradable microspheres. Biomaterials 2009; 31:2627-36. [PMID: 20035994 DOI: 10.1016/j.biomaterials.2009.12.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Accepted: 12/03/2009] [Indexed: 12/12/2022]
Abstract
One of the more substantial hurdles to be overcome in realizing the exciting potential of siRNA molecules as therapeutic agents for a wide range of diseases is the intact delivery of the active molecule into its target cell. Here, we present a platform for in vitro and in vivo delivery and intracellular release of siRNA in peritoneal macrophages (Mvarphis). The delivery platform is based on the encapsulation of siRNA in biodegradable poly(d,l-lactide) (PLA) microspheres, which are targeted to Mvarphis by the simple principle of size exclusion. Proof of concept was achieved using siRNAs targeting TNFalpha and CD86 in macrophages. We show that the release of the siRNA in peritoneal-derived macrophages in vitro occurs intracellularly, and is abrogated by cytochalasin B, a phagocytosis inhibitor. Silencing in these cells is potent and lasts for at least one week. In vivo, we prove that siRNA encapsulated in biodegradable PLA microspheres can be delivered to peritoneal-residing Mvarphis and can induce potent silencing of TNFalpha secretion for at least one week. The PLA microspheres hold great potential for in vivo use, due to their biocompatibility and degradability, and can potentially be used for in vivo immunomodulation of Mvarphis for treatment of autoimmune and chronic inflammatory conditions.
Collapse
Affiliation(s)
- Tali Brunner
- Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | | | | |
Collapse
|